1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Merck Went Own Way On Bezlotoxumab Endpoint And FDA May Not Follow

 
• By Brenda Sandburg

Merck rejected FDA's recommended endpoint to show efficacy in preventing C. difficile recurrence, which could make it difficult to gain approval for the product, headed to June 9 advisory panel review.

Merck & Co. Inc. chose not to use FDA's recommended primary endpoint for bezlotoxumab, a decision that could impede approval of the monoclonal antibody for prevention of Clostridium difficile infection (CDI) recurrence, a briefing document for an upcoming advisory committee review suggests. The agency says the clinical trial endpoint Merck used is difficult to interpret and may not show efficacy.

"While there appears to be a decrease in CDI recurrence with the use of bezlotoxumab, there is concern as to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers

US FDA’s Second Half 2025 User Fee Goals Swing Toward Respiratory Disease

 
• By Bridget Silverman

The 43 novel agents with user fee goal dates in the remainder of 2025 have fewer oncologics and infectious disease drugs than the first half of the year.

Slowdown: US FDA’s 2025 Novel Approvals Are On Below-Average Pace

 
• By Bridget Silverman

US FDA's 25 novel approvals in 2025 fell short of the agency's five-year average count, driven by a drop in drugs center approvals; 45 user fee goals remain in second half of year.

Global Pharma Guidance Tracker - June 2025

 
• By Vibha Sharma and Anabel Costa-Ferreira

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.